XML 19 R12.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Accrued Expenses | 3 Months Ended
--- | ---
Mar. 31, 2024
Accrued Liabilities, Current [Abstract] |
Accrued Expenses | 6. Accrued Expenses Accrued expenses consisted of the following (in thousands):
|  | As of March 31, 2024 |  |  | As of December 31, 2023 |
Accrued clinical and regulatory |  | $ | 190 |  |  | $ | 3,661 |
Accrued contract manufacturing cost |  |  | 1 |  |  |  | 1,100 |
Accrued compensation* |  |  | 1,170 |  |  |  | 3,948 |
Accrued other |  |  | 446 |  |  |  | 420 |
Total accrued expenses |  | $ | 1,807 |  |  | $ | 9,129 |
*Accrued compensation includes severance costs.

X
- Definition The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a),20,24) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_AccruedLiabilitiesCurrentAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration